Kymera Therapeutics Closes Upsized $225 Million Public Offering
Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Express News | Kymera Therapeutics Shares Reverse Course From Premarket; Last up 4%
Express News | Kymera Therapeutics Shares Down 4% Premarket After Co Prices $225 Mln Public Offering at $40.75 per Share
Biggest Stock Movers Today: PANW, FN, and More
All Securities Being Sold Offered by Kymera Therapeutics >KYMR
Express News | Kymera Therapeutics Inc - Shares of Common Stock Are Being Sold at a Public Offering Price of $40.75 per Share
Express News | Kymera Therapeutics Announces Pricing of $225 Million Public Offering
Express News | Kymera Therapeutics Shares Down 5.6% at $42.05 After the Bell Following Announcement of Stock Offering
Express News | Kymera Therapeutics Shares Are Trading Lower After the Company Began a $200 Million Public Offering of Common Stock and Pre-funded Warrants
Express News | Kymera Therapeutics: Commenced Underwritten Public Offering of $200.0 Mln of Shares of Its Common Stock
Express News | Kymera Therapeutics Announces Proposed Public Offering
Morgan Stanley Maintains Kymera Therapeutics(KYMR.US) With Hold Rating, Maintains Target Price $45
Kymera Therapeutics Is Maintained at Equal-Weight by Morgan Stanley
Morgan Stanley Maintains Kymera Therapeutics(KYMR.US) With Hold Rating, Raises Target Price to $45
Express News | Kymera Therapeutics Inc : Morgan Stanley Raises Target Price to $45.00 From $34.00
Balancing Pipeline Potential and Clinical Risks: Kymera Therapeutics' Strategic Update and Hold Rating
Analysts Offer Insights on Healthcare Companies: Illumina (ILMN), Kymera Therapeutics (KYMR) and Viridian Therapeutics (VRDN)
Unveiling 6 Analyst Insights On Kymera Therapeutics
Express News | Wells Fargo Maintains Equal-Weight on Kymera Therapeutics, Raises Price Target to $38
No Data